Unknown

Dataset Information

0

Safety and efficacy of a standardized intracameral combination of mydriatics and anesthetic for cataract surgery in type-2 diabetic patients.


ABSTRACT: BACKGROUND:Cataract surgery in diabetics is more technically challenging due to a number of factors including poor intraoperative pupil dilation and a higher risk of vision threatening complications. This study evaluates the safety and efficacy of an intracameral combination of 2 mydriatics and 1 anesthetic (ICMA, Mydrane) for cataract surgery in patients with well-controlled type-2 diabetes. METHODS:Post-hoc subgroup analysis of a phase 3 randomized study, comparing ICMA to a conventional topical regimen. Data were collected from 68 centers in Europe and Algeria. Only well-controlled type-2 diabetics, free of pre-proliferative retinopathy, were included. The results for non-diabetics are also reported. The primary efficacy variable was successful capsulorhexis without additional mydriatic treatment. Postoperative safety included adverse events, endothelial cell density and vision. RESULTS:Among 591 randomized patients, 57 (9.6%) had controlled type 2 diabetes [24 (42.1%) in the ICMA Group and 33 (57.9%) in the Topical Group; intention-to-treat (ITT) set]. Among diabetics, capsulorhexis was successfully performed without additional mydriatics in 24 (96.0%; modified-ITT set) patients in the ICMA Group and 26 (89.7%) in the Topical Group. These proportions were similar in non-diabetics. No diabetic patient [1 (0.5%) non-diabetics] in the ICMA Group had a significant decrease in pupil size (?3?mm) intraoperatively compared to 4 (16.0%; modified-ITT set) diabetics [16 (7.3%) non-diabetics] in the Topical group. Ocular AE among diabetics occurred in 2 (8.0%; Safety set) patients in the ICMA Group and 5 (16.7%) in the Topical Group. Endothelial cell density at 1?month postoperatively was similar between groups in diabetics (P?=?0.627) and non-diabetics (P?=?0.368). CONCLUSIONS:ICMA is effective and can be safely used in patients with well-controlled diabetes, with potential advantages compared to a topical regimen including reduced systemic risk, better corneal integrity and reduced risk of ocular complications. TRIAL REGISTRATION:The trial was registered at (reference # NCT02101359) on April 2, 2014.

SUBMITTER: Labetoulle M 

PROVIDER: S-EPMC7055021 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Safety and efficacy of a standardized intracameral combination of mydriatics and anesthetic for cataract surgery in type-2 diabetic patients.

Labetoulle Marc M   Behndig Anders A   Tassignon Marie-José MJ   Nuijts Rudy R   Mencucci Rita R   Güell José Luis JL   Pleyer Uwe U   Szaflik Jacek J   Rosen Paul P   Bérard Alain A   Chiambaretta Frédéric F   Cochener-Lamard Béatrice B  

BMC ophthalmology 20200303 1


<h4>Background</h4>Cataract surgery in diabetics is more technically challenging due to a number of factors including poor intraoperative pupil dilation and a higher risk of vision threatening complications. This study evaluates the safety and efficacy of an intracameral combination of 2 mydriatics and 1 anesthetic (ICMA, Mydrane) for cataract surgery in patients with well-controlled type-2 diabetes.<h4>Methods</h4>Post-hoc subgroup analysis of a phase 3 randomized study, comparing ICMA to a con  ...[more]

Similar Datasets

| S-EPMC4941138 | biostudies-literature
| S-EPMC5549410 | biostudies-other
| S-EPMC6041193 | biostudies-literature
| S-EPMC7508123 | biostudies-literature
| S-EPMC8184599 | biostudies-literature
| S-EPMC10214589 | biostudies-literature
| S-EPMC6325070 | biostudies-literature
| S-EPMC4073666 | biostudies-literature
| S-EPMC6288531 | biostudies-other
| S-EPMC8482333 | biostudies-literature